Search | VHL TCIM Americas

Effects of UK 69 578: a novel atriopeptidase inhibitor.

Northridge, D B; Jardine, A G; Alabaster, C T; Barclay, P L; Connell, J M; Dargie, H J; Dilly, S G; Findlay, I N; Lever, A F; Samuels, G M.

Lancet ; 2(8663): 591-3, 1989 Sep 09.

Article in English | MEDLINE | ID: mdl-2570286

ABSTRACT

UK 69 578 is a competitive inhibitor of endopeptidase 24.11 (the enzyme that degrades atrial natriuretic factor) in vitro. In vivo, UK 69 578 has renal and cardiovascular effects similar to low-dose atrial natriuretic factor infusion, and may be a useful agent in hypertension and heart failure.

Subject(s)

Atrial Natriuretic Factor/antagonists & inhibitors , Cyclohexanecarboxylic Acids , Neprilysin/antagonists & inhibitors , Animals , Atrial Natriuretic Factor/blood , Clinical Trials as Topic , Coronary Disease/blood , Coronary Disease/drug therapy , Dogs , Dose-Response Relationship, Drug , Double-Blind Method , Drug Evaluation , Drug Evaluation, Preclinical , Half-Life , Humans , Infusions, Intravenous , Male , Middle Aged , Natriuresis/drug effects , Nephrectomy , Neprilysin/blood , Neprilysin/pharmacology , Rats , Rats, Inbred Strains , Time Factors

ABSTRACT

Subject(s)

SEND TO:

SELECTION OF CITATIONS

SEARCH DETAIL